TDOG 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-05-13

• The Trust’s investment objective is to seek to track the performance of Dogecoin, as measured by the performance of the Pricing Benchmark, adjusted for the Trust’s expenses and other liabilities. CF Benchmarks Ltd. is the Pricing Benchmark Provider. The Pricing Benchmark is designed to reflect the p…

• Because the Trust had no investment operations prior to January 21, 2026 (the Seed Capital Purchase Date), the results of operations for the three months ended March 31, 2026 and the six months ended March 31, 2026 are identical and are discussed together below.

• Although the six-month period covered by this report runs from October 1, 2025 through March 31, 2026, the Trust had no investment operations prior to January 21, 2026, and accordingly, the results of operations reflect activity from January 21, 2026 through March 31, 2026. The Trust’s NAV increased…

• Net decrease in net assets resulting from operations for both periods was $(636,693), resulting from a net change in unrealized depreciation on investment in Dogecoin of $(634,598), a net realized loss of $(507) from Dogecoin sold to pay the Sponsor Fee, and a net investment loss of $(1,735), partia…

• *No prior comparative period is presented as the Trust had no investment operations during the three and six months ended March 31, 2025.

相对上期删除的文字 · 来源:10-Q · 2026-02-20

• The Trust’s investment objective is to seek to track the performance of Dogecoin, as measured by the performance of the CF Dogecoin-Dollar US Settlement Price Index (the “Pricing Benchmark”), adjusted for the Trust’s expenses and other liabilities. The Pricing Benchmark is calculated by CF Benchmark…

• As of December 31, 2025, the Constituent Exchanges included in the Pricing Benchmark that is utilized by the Trust are Coinbase, Gemini, Kraken, Bitstamp, and Crypto.com. Gemini’s headquarters are located in New York, New York, and Gemini is registered as a money services business with FinCEN and ho…

• The Trust is not aware of any trends, demands, commitments, events, or uncertainties that are reasonably likely to result in material changes to its liquidity needs. The Trust’s only ordinary recurring expense is expected to be the fee paid to the Sponsor at an annual rate of 0.50% of the Trust’s to…

• The Sponsor is not required to pay any extraordinary or non-routine expenses. Extraordinary expenses are fees and expenses which are unexpected or unusual in nature, such as legal claims and liabilities and litigation costs or indemnification or other unanticipated expenses. Extraordinary fees and e…

相对上期新增的文字 · 来源:10-Q · 2026-05-13

• You should carefully consider the risk factors discussed below as well as the risk factors discussed in Part I, Item 1A. “Risk Factors” in our Annual Report, which could materially affect our business, financial condition or future results. Other than as described herein, there have been no material…

• The Trust Agreement includes a provision restricting Shareholders’ right to bring a derivative action.

• Under Section 7.4 of the Trust Agreement, Shareholders’ ability to bring a derivative action (i.e., to initiate a lawsuit in the name of the Trust in order to assert a claim belonging to the Trust against a fiduciary of the Trust or against a third-party when the Trust’s management has refused to do…

• In addition to the 10% ownership threshold described above, the Trust Agreement imposes the following further procedural conditions on any Shareholder seeking to bring a derivative action on behalf of the Trust: (1) prior to bringing any such action, two or more non-affiliated Shareholders collectiv…

• These provisions apply to any derivative actions brought in the name of the Trust other than derivative claims brought under the federal U.S. securities laws and the rules and regulations thereunder. The enforceability of Section 7.4’s derivative action threshold and procedural requirements under ap…

相对上期删除的文字 · 来源:10-Q · 2026-02-20

• You should carefully consider the risk factors discussed in “Risk Factors” in our Registration Statement on Form S-1 (333-286456) (our “Registration Statement”) declared effective on January 9, 2026, and the prospectus contained therein (the “Prospectus”), which could materially affect our business,…